Addressing the Role of Angiogenesis in Patients with Advanced Pancreatic Neuroendocrine Tumors Treated with Everolimus: A Biological Prospective Analysis of Soluble Biomarkers and Clinical Outcomes

Pharmacogenomic analyses of sunitinib in patients with pancreatic neuroendocrine tumors

(2019) Nicola Fazio et al.   Future Oncology

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors

(2017) Jonathan Strosberg et al.   NEW ENGLAND JOURNAL OF MEDICINE

Predictive Markers of Response to Everolimus and Sunitinib in Neuroendocrine Tumors

(2017) Diana Martins et al.   Targeted Oncology

Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 Study

(2016) James C. Yao et al.   JOURNAL OF CLINICAL ONCOLOGY

Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumours

(2015) A J Zurita et al.   BRITISH JOURNAL OF CANCER

Insight into the Effect of Inhibitor Resistant S130G Mutant on Physico-Chemical Properties of SHV Type Beta-Lactamase: A Molecular Dynamics Study

(2014) Mohd Hassan Baig et al.   PLoS One

An expression signature of the angiogenic response in gastrointestinal neuroendocrine tumours: correlation with tumour phenotype and survival outcomes

(2013) D J Pinato et al.   BRITISH JOURNAL OF CANCER

Prognostic Significance of MTOR Pathway Component Expression in Neuroendocrine Tumors

(2013) Zhi Rong Qian et al.   JOURNAL OF CLINICAL ONCOLOGY

Pericyte coverage of differentiated vessels inside tumor vasculature is an independent unfavorable prognostic factor for patients with clear cell renal cell carcinoma

(2012) Yun Cao et al.   CANCER

Pericyte Depletion Results in Hypoxia-Associated Epithelial-to-Mesenchymal Transition and Metastasis Mediated by Met Signaling Pathway

(2012) Vesselina G. Cooke et al.   CANCER CELL

Angiogenesis in Neuroendocrine Tumors: Therapeutic Applications

(2012) Jean-Yves Scoazec   NEUROENDOCRINOLOGY

Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors

(2011) Eric Raymond et al.   NEW ENGLAND JOURNAL OF MEDICINE

Everolimus for Advanced Pancreatic Neuroendocrine Tumors

(2011) James C. Yao et al.   NEW ENGLAND JOURNAL OF MEDICINE

Circulating perivascular progenitors: A target of PDGFR inhibition

(2010) Patrizia Mancuso et al.   INTERNATIONAL JOURNAL OF CANCER

mTOR Inhibitor RAD001 (Everolimus) Has Antiangiogenic/Vascular Properties Distinct from a VEGFR Tyrosine Kinase Inhibitor

(2009) H. A. Lane et al.   CLINICAL CANCER RESEARCH

Predictive Potential of Angiogenic Growth Factors and Circulating Endothelial Cells in Breast Cancer Patients Receiving Metronomic Chemotherapy Plus Bevacizumab

(2009) A. Calleri et al.   CLINICAL CANCER RESEARCH

Pancreatic Endocrine Tumors: Expression Profiling Evidences a Role for AKT-mTOR Pathway

(2009) Edoardo Missiaglia et al.   JOURNAL OF CLINICAL ONCOLOGY

Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival

(2008) T. R. Halfdanarson et al.   ANNALS OF ONCOLOGY

Validation of a Standardized Method for Enumerating Circulating Endothelial Cells and Progenitors: Flow Cytometry and Molecular and Ultrastructural Analyses

(2008) P. Mancuso et al.   CLINICAL CANCER RESEARCH

Metronomic Cyclophosphamide and Capecitabine Combined With Bevacizumab in Advanced Breast Cancer

(2008) Silvia Dellapasqua et al.   JOURNAL OF CLINICAL ONCOLOGY